|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 200 Lawyers Road NW #1506 |
Address2 |
|
City | Vienna |
State | VA |
Zip Code | 22183 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 35627-12
|
||||||||
|
6. House ID# 327060000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Karen Kerrigan |
Date | 5/22/2020 4:10:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
COVID 19 Response
Supported broad measures to provide capital, regulatory and tax relief and support to small businesses in response to the COVID-19 economic crisis. Also supported liability reform (a liability shield), reforming the Paycheck Protection Program (PPP) once signed into law, as well as the Economic Injury Disaster Loan (EIDL) program. Expressed concerns about paid-leave mandates and other burdens on small businesses during the COVID-19 crisis.
Specific legislative efforts included:
Coronavirus Aid, Relief, and Economic Security (CARES) Act: Supported House and Senate passage.
PPP Reform: Advocated to extend the June 30 covered period to year-end, providing flexibility in the 8-week window to 24 weeks, repealing the 75-25 forgivable expense ratio, and allowing for technology/software costs to be included as a forgivable expense.
Tax Relief: Continue to support efforts on payroll tax relief, and making the small-business provisions of the Tax Cuts and Relief Act permanent.
FinTech Lenders: Voiced strong support for allowing fin-tech lenders to receive approval for PPP loan processing and loan disbursement.
Voiced support for second tranche of PPP funds advanced by Congress.
Access to Capital
SEC Harmonization Rules: Voiced support for Securities and Exchange Commissions proposed changes to improve capital access for small businesses, including those related to regulation crowdfunding that would make it more practical and affordable for small businesses.
Crowdfunding Improvements: Advocacy efforts continued for urging Congress to support updates to regulation crowdfunding, including: raising the cap from $1.07 million to $10 million, revising individual investors limits, streamlining compliance and related measures.
Regulation
Protecting the Right to Organize Act (PRO Act), H.R. 2474: Against House passage.
Comments to Surface Transportation Board: Supported efforts to adopt cost-benefit analysis for rulemakings.
Comments to the Council on Environmental Quality: In support of proposed National Environmental Policy Act reforms.
Comments to the Federal Drug Administration: Expressed opposition to the importation of Prescriptions Drugs.
Joint Employer: Voiced support for the Department of Labors final joint employer rules.
Voiced support for ongoing efforts to develop a national governing framework for privacy and data regulation.
Trade
United-States-Mexico Agreement (USMCA): Continued to voice support for the agreement including U.S. Senate passage and its signing by President Trump.
Buy American Executive Order: Expressed concerns about the order, including new costs and restrictions on market access for U.S. small businesses.
Expressed support for a new free trade agreement with Taiwan.
Defending American Security from Kremlin Aggression Act (DASKA): Expressed concern about how the downstream impact of DASKA would effect the small business supply chain in the U.S.
Broadband Access
$20.4 billion Rural Digital Opportunity Fund: Supported the Federal Communications Commission (FCC) final rules on the fund.
Spectrum: Voiced support for FCCs proposal on the use of the C-band spectrum to make more available for 5G.
Government Reform
Comments to Postal Regulatory Commission: Regarding USPSs financial condition and the need for improved financial management Commission to thoroughly reconsider its proposal that would enable the Postal Service to significantly increase mail prices on services that are already financially effective. Also provided comments on the need for USPS to focus on reforms and changes on inefficiencies and failures in achieving proposed cost savings that have caused the USPS to withstand recurring financial losses for the last decade.
Nominations
Jovita Carranza as SBA Administrator: Expressed support to the U.S. Senate for this nomination and confirmation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Small Business Administration (SBA), Federal Communications Commission (FCC), Postal Regulatory Commission, Council on Environmental Quality (CEQ), Food & Drug Administration (FDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karen |
Kerrigan |
|
|
|
Raymond |
Keating |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |